6 results
8-K
EX-99.1
MLYS
Mineralys Therapeutics Inc
21 Mar 24
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:43am
of Mineralys Therapeutics. “In 2024, we are working towards achieving several clinical events, which we expect to expand the data package for lorundrostat. We
S-3
EX-1.2
MLYS
Mineralys Therapeutics Inc
21 Mar 24
Shelf registration
7:30am
is declared effective by the Commission.
“General Disclosure Package” means each Issuer General Use Free Writing Prospectus, if any, issued prior … the statements therein not misleading. At each Applicable Time, neither (A) the General Disclosure Package nor (B) any individual Issuer Limited Use
DRS/A
MLYS
Mineralys Therapeutics Inc
29 Dec 22
Draft registration statement (amended)
12:00am
was captured using the 24-hour ABPM via an integrated software package that measures the pulse waveform and thus obtains central BP measurements
DRS/A
MLYS
Mineralys Therapeutics Inc
7 Dec 22
Draft registration statement (amended)
12:00am
in this trial was captured using the 24-hour ABPM via an integrated software package that measures the pulse waveform and thus obtains central BP measurements
DRS
8rtx9lurq1e0n3 cil
4 Nov 22
Draft registration statement
12:00am
- Prev
- 1
- Next